SCHEMBL23012256

SCHEMBL23012256

COC(=O)c1cc(Cl)c(C2CCN(C)CC2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
MAPK1 P28482 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39
SLC6A3 Q01959 3/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SSTR4 P31391 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
QDPR P09417 1/20 0.35
CYP2C19 P33261 1/20 0.35
SSTR1 P30872 1/20 0.35
HTR4 Q13639 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23334341 0.89 SLC6A3 (0.46) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL23013340 0.87 DAO (0.45) ALDH1A1KMT2AMEN1KDM4ETRPV4
SCHEMBL23012824 0.78 HTR4 (0.40) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL23013272 0.76 HTR4 (0.43) SLC6A3SLC6A2SLC6A4SSTR4SSTR1
SCHEMBL23012749 0.74 LMNA (0.44) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL25172126 0.74 MAPT (0.49) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL14164234 0.71 HRH3 (0.42) SMN1; SMN2SSTR4
SCHEMBL31322845 0.71 HPGD (0.41) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL3308515 0.70 ALDH1A1 (0.42) ALDH1A1CYP1A2KMT2AMEN1KDM4E
SCHEMBL25130803 0.69 REV1 (0.39) ALDH1A1KMT2AMEN1HPGDTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289727-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-09-15 US disclosed
EP-4017850-A1 ENZYME INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-29 EP disclosed
CN-114258392-A Enzyme inhibitors 卡尔维斯塔制药有限公司 2022-03-29 CN disclosed
WO-2021032935-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 WO disclosed
WO-2021032938-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 WO disclosed
WO-2021032938-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 WO disclosed
WO-2021032935-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289727-A1 ENZYME INHIBITORS SERPINB1, ACE, GAA ALDH1A1 237/4885CYP1A2 17/4885KMT2A 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.